Document 0945
 DOCN  M9470945
 TI    Toward a vaccine for AIDS: the emergence of immunobiology-based vaccine
       development.
 DT    9409
 AU    Cease KB; Berzofsky JA; Department of Internal Medicine, University of
       Michigan, Ann; Arbor.
 SO    Annu Rev Immunol. 1994;12:923-89. Unique Identifier : AIDSLINE
       MED/94280791
 AB    Over a decade has passed since the identification of the human
       immunodeficiency virus (HIV) as the causative agent of AIDS. During this
       time, HIV has been extensively characterized, and a variety of vaccine
       constructs and strategies have been explored. For the most part, these
       have been driven by successes of the past with other pathogens, or by
       novel approaches enabled by technologies of the present. With the
       maturing of our insights into the immunopathology of HIV and basic
       immunological mechanisms, we are presented with unprecedented
       opportunities to rationally develop vaccine approaches strategically
       designed to counter the immunopathology of HIV. As opposed to absolute
       prevention of infection, the primary goal of these strategies may be to
       limit infection and to assure a response to infection that prevents
       disease and transmission. Thus, such vaccines may find utility in both
       preventive and therapeutic roles. In this paper, we present the
       background and current state of immunobiology-driven vaccine development
       for AIDS.
 DE    Antigenic Determinants/IMMUNOLOGY  AIDS Vaccines/*IMMUNOLOGY  Human  HIV
       Antibodies/BIOSYNTHESIS  Support, U.S. Gov't, P.H.S.
       T-Lymphocytes/PHYSIOLOGY  Vaccines, Synthetic/IMMUNOLOGY  JOURNAL
       ARTICLE  REVIEW  REVIEW, ACADEMIC

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).